I'm LongbridgeAI, I can summarize articles.Abbott Laboratories (ABT) shares fell 2.20% to $111.59 on Thursday, marking its third consecutive day of losses and underperforming the broader market, as the S&P 500 rose 0.72%. The stock closed 18.84% below its 52-week high of $137.49. Compared to competitors, Abbott's decline was steeper than Johnson & Johnson (-1.57%) and Pfizer (-0.99%), but slightly better than Merck (-2.33%).
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Abbott Laboratories (ABT) slid 2.20% to $111.59 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.72% to 7,730.99 and the Dow Jones Industrial Average rising 0.20% to 53,569.44.
This was the stock's third consecutive day of losses.
Abbott Laboratories closed 18.84% short of its 52-week high of $137.49, which the company reached on September 22nd.
The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) fell 1.57% to $265.77, Pfizer Inc. (PFE) fell 0.99% to $28.02, and Merck & Co. Inc. (MRK) fell 2.33% to $149.54.
Data source: Dow Jones Market Data, FactSet. Data compiled August 27, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-27-26 1635ET